<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig1">
 <label>Fig. 1</label>
 <caption>
  <p>Opioids exacerbate HIV-1-induced CNS inflammation, in part, by augmenting CCL5-dependent increases in CCL2—key sites of opioid-HIV convergent interactions in glial inflammatory signaling cascades. Subpopulations of striatal glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes in wildtype mice normally express CCR2 immunoreactivity (
   <bold>a-b</bold>; 
   <italic>arrows</italic>), CCL2 (
   <bold>c</bold>; 
   <italic>arrow</italic>), or μ-opioid receptor (MOR) (
   <bold>d</bold>; 
   <italic>arrows</italic>) immunoreactivity (scale bars 
   <bold>a-b</bold> = 25 μm; 
   <bold>c-d</bold> = 15 μm). CCR2 deletion (−/−) significantly reduces HIV-1 Tat ± morphine-induced increases in GFAP+ astroglia (
   <bold>e</bold>) and F4/80+ macrophages/microglia (
   <bold>f</bold>) compared to wild type (+/+) mice at sites near (300 ± 100 μm) the site of Tat injection (*
   <italic>p</italic> &lt; 0.05 vs. wild type mice) (see, El-Hage et al. 
   <xref ref-type="bibr" rid="CR131">2006a</xref>). In wild-type mice, Tat ± morphine administration markedly increases the proportion of CCL2 immunoreactive astrocytes (
   <bold>g</bold>) or macrophages/microglia (
   <bold>h</bold>) [*
   <italic>p</italic> &lt; 0.05 vs. other groups in wild-type or CCL5(−/−) mice; 
   <sup>b</sup>
   <italic>p</italic> &lt; 0.05 vs. vehicle- or Tat plus morphine-treated wild-type mice; 
   <sup>#</sup>
   <italic>p</italic> &lt; 0.05 vs. equivalent treatment in wild-type mice], while in CCL5 null mice, significant increases in CCL2 immunoreactivity were only seen in macrophages/microglia co-exposed to Tat and morphine (
   <sup>§</sup>
   <italic>p</italic> &lt; 0.05 vs. vehicle injected CCL5 knockout mice) (see, El-Hage et al. 
   <xref ref-type="bibr" rid="CR133">2008a</xref>). CCL5 expression in striatal GFAP-immunoreactive astrocytes (
   <italic>arrows</italic>) increases following Tat injections (
   <bold>i, j</bold>) compared to wild-type control mice (
   <italic>not shown</italic>) (El-Hage et al. 
   <xref ref-type="bibr" rid="CR133">2008a</xref>). Opioids exacerbate HIV-1-induced CNS inflammation, in part, by increasing CCL5 and augmenting CCR5-dependent increases in CCL2 production by astrocytes resulting in the activation and recruitment of microglia/macrophages and spiraling inflammation (
   <bold>k</bold>). Additional factors likely mediate the proinflammatory cascade, but these are less well substantiated (
   <italic>?</italic>). Moreover, autocrine and reciprocal paracrine (
   <italic>astroglial ↔ macrophage/microglial</italic>) intercellular, feedback amplification mechanisms from macrophages/microglia are likely to be operative (
   <italic>dashed red arrow</italic>) (also see, Kang and Hebert 
   <xref ref-type="bibr" rid="CR229">2011</xref>) and occur elsewhere within the cascade (
   <italic>not shown</italic>); effects of HIV-1 Tat/HIV, 
   <italic>red arrows</italic>; sites of opioid convergence, 
   <italic>blue arrows</italic>; pro-BDNF:mature BDNF (mBDNF) ratio (Kim et al. 
   <xref ref-type="bibr" rid="CR237">2018</xref>). (
   <bold>a-f</bold>) Modified and reprinted with permission from El-Hage et al. (
   <xref ref-type="bibr" rid="CR131">2006a</xref>). (
   <bold>g-k</bold>) Modified and reprinted with permission from El-Hage et al. (
   <xref ref-type="bibr" rid="CR133">2008a</xref>)
  </p>
 </caption>
 <graphic xlink:href="11481_2020_9941_Fig1_HTML" id="MO2" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
